In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.
Focused Solutions for Oncology
Pieris Pharmaceuticals is proud to partner with industry leaders in immuno-oncology. Read how these key partnerships are helping us produce superior outcomes for patients.
Immuno-Oncology
Candidate
Targets
Partner
Discovery
Preclinical
Phase 1
Phase 2
Candidate
PRS-346/SGN-BB228
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
PRS-342/BOS-342
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
Candidate Seagen Programs‡
Partner
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
‡ 2 active bispecific programs in collaboration with Pfizer in addition to PRS-346/SGN-BB228 listed above.